Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBITDA: 2010-2024

Historic EBITDA for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to -$95.0 million.

  • Altimmune's EBITDA rose 15.59% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.1 million, marking a year-over-year increase of 18.55%. This contributed to the annual value of -$95.0 million for FY2024, which is 7.71% down from last year.
  • Per Altimmune's latest filing, its EBITDA stood at -$95.0 million for FY2024, which was down 7.71% from -$88.2 million recorded in FY2023.
  • In the past 5 years, Altimmune's EBITDA registered a high of -$49.1 million during FY2020, and its lowest value of -$97.1 million during FY2021.
  • For the 3-year period, Altimmune's EBITDA averaged around -$89.4 million, with its median value being -$88.2 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 139.36% in 2020, then increased by 12.55% in 2022.
  • Over the past 5 years, Altimmune's EBITDA (Yearly) stood at -$49.1 million in 2020, then plummeted by 97.86% to -$97.1 million in 2021, then increased by 12.55% to -$84.9 million in 2022, then dropped by 3.92% to -$88.2 million in 2023, then fell by 7.71% to -$95.0 million in 2024.